Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMWH lead-in followed by dabigatran for acute intermediate-risk pulmonary embolism
2015-001830-12Phase 4Completed
- Sponsor
- University Medical Center Mainz
- Start
- Jul 2015
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dabigatran and low molecular weight heparin calcium in pulmonary embolism (PE) and venous thromboembolism (VTE), sponsored by University Medical Center Mainz. Primary endpoint: Symptomatic venous thromboembolism or pulmonary embolism-related death within 6 months. Started Jul 2015; status: completed.
02
Drugs
dabigatranlow molecular weight heparin calcium
03
Conditions
pulmonary embolism (PE)venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2015-001830-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001830-12.